Macrophage Therapeutics, Inc., a subsidiary of Navidea
Biopharmaceuticals, Inc. (NYSE MKT:NAVB), today announced the
appointment of leading experts to a newly formed scientific
advisory board (SAB) to serve as a strategic resource to Macrophage
Therapeutics as it looks to develop therapeutic applications for
Navidea’s innovative Manocept™ platform. The inaugural SAB
consortium is comprised of world-renowned scientists and clinicians
in the areas of oncology, immunology, autoimmune diseases and
macrophage biology. The SAB will serve as an ongoing resource to
provide management with counsel and guidance pertaining to the
research, development, and clinical application of Manocept
technology.
“While Macrophage Therapeutics is a newly created entity, the
proprietary Manocept technology on which it is based, is well
advanced. The demonstrated activity in immunotherapy of the
platform suggests promise in a broad range of therapeutic areas. In
order to ensure the most rapid development of products that address
markets with large unmet medical needs, we are creating an advisory
board committed to being actively engaged with management to
evaluate and prioritize opportunities. The SAB is initially
comprised of scientists who have had direct experience with our
technology as well as prominent experts in the area of immunology.
This board will be augmented with experts with specific therapeutic
area expertise as potential applications grow,” said Michael
Goldberg, M.D., Navidea Director and Macrophage Therapeutics Chief
Executive Officer. “In addition, the previously announced initial
funding for Macrophage Therapeutics is progressing towards closing
next week.”
"We believe the Manocept platform may provide important new
opportunities across a range of clinical indications where
significant unmet medical need exists," stated Frederick O. Cope,
Ph.D., FACN, Navidea Senior Vice President and Chief Scientific
Officer. "We are very pleased to bring together these key thought
leaders to establish the Macrophage Therapeutics Scientific
Advisory Board. Their deep insight into macrophage science and
macrophage-mediated diseases will be instrumental in prioritizing
and advancing our therapeutic research programs."
The inaugural members of Macrophage Therapeutics’ Scientific
Advisory Board include:
Siamon Gordon, M.B., Ch.B.,
Ph.D.Glaxo Wellcome Professor of Cellular Pathology
(Emeritus), University of Oxford
Mark I. Greene, M.D., Ph.D.,
F.R.C.P.John Eckman Professor of Medical Sciences, Vice
Chair of Pathology, Division of Immunology and Experimental
Pathology, University of Pennsylvania
Wael Jarjour, M.D.Associate
Professor, Director, Division of Rheumatology & Immunology, The
Ohio State University
Michael S. McGrath, M.D.,
Ph.D.Professor, Departments of Laboratory Medicine,
Pathology, and Medicine, University of California San Francisco
Thomas J. Rosol, D.V.M.,
Ph.D.Professor, Veterinary Sciences, The Ohio State
University; Senior Advisor, Life Sciences, University Office of
Technology Commercialization and Knowledge Transfer, The Ohio State
University; Special Assistant to the Vice President for Research,
The Ohio State University
Eric K. Rowinsky, M.D.Head
of Research and Development and Chief Medical Officer,Stemline
Therapeutics, Inc. and Director of Navidea Biopharmaceuticals
Larry S. Schlesinger,
M.D.Chair, Department of Microbial Infection and
Immunity, Director, Center for Microbial Interface Biology, The
Ohio State University
David Sidransky,
M.D.Professor of Otolaryngology – Head and Neck Surgery,
Professor of Oncology, Professor of Pathology, Professor of
Cellular & Molecular Medicine, Professor of Urology, and
Director, Head and Neck Cancer Research, The Johns Hopkins
University
Kenneth C. Williams,
Ph.D.Professor of Biology, Boston College
About Macrophage Therapeutics
Macrophage Therapeutics, a newly created subsidiary of Navidea
Biopharmaceuticals, Inc., is developing innovative
macrophage-targeted therapies for oncology, inflammatory,
autoimmune and cardiovascular applications based on Navidea’s
proprietary CD206 targeting technology platform, Manocept™.
Depending on the active agent(s) attached to the Manocept backbone
as well as other core molecule permutations, it is possible to
approach immunotherapy in a completely novel manner. This approach
has the potential to provide for management and modification of
diseases that include the immediate involvement of macrophages, the
biological products of macrophages, or the effective impact of
macrophages or their progenitor and/or daughter elements. Thus, the
Manocept platform is designed to specifically address a key
element, macrophage interactions, in the natural progression of
clinically significant diseases that impact the lives of patients
around the globe.
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision diagnostics, therapeutics and
radiopharmaceutical agents. Navidea is developing multiple
precision-targeted products and platforms including Manocept™,
NAV4694, and NAV5001, to help identify the sites and pathways of
undetected disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and by the EMA in November 2014. Navidea’s
strategy is to deliver superior growth and shareholder return by
bringing to market novel radiopharmaceutical agents and
therapeutics and advancing the Company’s pipeline through global
partnering and commercialization efforts. For more information,
please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Macrophage Therapeutics, Inc.Michael M. Goldberg, M.D.
201-608-5218orNavidea BiopharmaceuticalsBrent Larson,
614-822-2330Executive VP & CFOorSharon Correia,
978-655-2686Associate Director, Corporate Communications
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024